Visualization, analysis, reporting, lesion measurement, kinetic assessment, and MR-guided breast interventional planning; when interpreted by a skilled physician, information may support screening, diagnosis, and intervention planning, but patient management must not rely solely on the results.
Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.
Clinical fit
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact purpose
Visualization, analysis, reporting, lesion measurement, kinetic assessment, and MR-guided breast interventional planning; when interpreted by a skilled physician, information may support screening, diagnosis, and intervention planning, but patient management must not rely solely on the results.
FDA source Exact FDA submission Checked 2026-09-09
Breast MRI visualization, semi-automatic lesion segmentation and measurement, kinetic analysis and reporting, follow-up review, and MR-guided interventional planning.
FDA source Exact FDA submission Checked 2026-09-09
DCE-MRI breast image series in DICOM format accessed through Olea Sphere V3.0, with mammography and ultrasound series available for display-only viewing.
FDA source Exact FDA submission Checked 2026-09-09
Registered MR viewing, subtractions, kinetic curves and semi-quantitative maps, semi-automatic lesion segmentation, lesion volume and 2D/3D diameter, distances to nipple, chest, and skin, BI-RADS annotations and breast-sector localization, follow-up layouts, and BreastLoc outputs for needle block position, insertion point, introducer depth, and insertion-path display.
FDA source Exact FDA submission Checked 2026-09-09
breastscape V1.0 is not intended for primary interpretation of digital mammography. Lossy-compressed mammographic images and digitized film-screen images must not be used for primary interpretation. A skilled physician must interpret the information, and patient-management decisions must not be based solely on the results.
FDA source Exact FDA submission Checked 2026-09-09
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
FDA submission
K211431
FDA source Exact FDA submission Checked 2026-08-31
Use these fields to structure a vendor demo, security review, and implementation estimate.
Integration
The device is an optional PACS module that requires the cleared Olea Sphere V3.0 PACS viewer (K152602), its data and license-management services, and operational use of that package. It accesses MR image series in DICOM format through Olea Sphere V3.0; a specific local PACS or RIS interface beyond that dependency is not established.
FDA source Exact FDA submission Checked 2026-09-09
Public source Exact FDA submission Checked 2026-08-13
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
ACR AI Central provides an exact-submission model card for breastscape v1.0; FDA labeling remains controlling for clinical use, limitations, and performance.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.
Evidence summary
Olea Medical reports extensive internal verification and validation covering product risk assessment, software-module verification, and software validation for the Olea Sphere V3.0 system. The packet also references a pivotal clinical study and additional comparisons with MultiView MR Breast for BreastLoc, direct manual measurements for BreastApp metrics and maps, and validation of reporting, follow-up, mammography loading, and visualization; no numeric sensitivity, specificity, AUC, Dice, or reader-delta endpoint is reported in the packet.
FDA source Exact FDA submission Checked 2026-09-09
Needs research Exact FDA submission Checked 2026-08-31
This field has not been curated yet.
Reported specificity
Research pending
Needs research Exact FDA submission Checked 2026-08-31
This field has not been curated yet.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
breastscape v1.0 regulatory performance study summary
Unspecified · Population described in the exact-submission ACR model card
exact submission · Tested version: Exact product version not reported; regulatory study summarized for FDA submission K211431 · Independence not established
K211431
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
These are common procurement questions; unknown values remain visible until a source supports them.
Pricing and total cost
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-09
No public price or quote for the exact K211431 configuration was established in this review.
Reimbursement and coding
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-09
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K211431. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Public source Exact FDA submission Checked 2026-09-09
Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Verify pricing and total cost: No public price or quote for the exact K211431 configuration was established in this review.
Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-09Last searched
22Fields reviewed
9Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR provides bounded exact-submission catalog context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
cmAngio (V1.6) processes screening mammograms to aid a qualified interpreting physician in the manual process of identifying breast arterial calcification. It detects the presence...
cmAngio processes screening FFDM and DBT mammograms to detect presence or absence of breast arterial calcifications at study and breast level and mark segments for qualified...
Quantra version 2.1 calculates volumetric and area breast-density measures and density categories from supported digital mammography images as an adjunct, not a diagnostic result.